Variation at the DPP4 locus influences apolipoprotein B levels in South Asians and exhibits heterogeneity in Europeans related to BMI

Diabetologia

Volumn 57, Issue 4, 2014, Pages 738-745

  Bailey, Swneke D ^a   Xie, Changchun ^b,c,f   Paré, Guillaume ^b,c   Montpetit, Alexandre ^a   Mohan, Viswanathan ^d   Yusuf, Salim ^b,c   Gerstein, Hertzel ^b,c   Engert, James C ^a,e   Anand, Sonia S ^b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d MADRAS DIABETES RESEARCH FOUNDATION   (India)

^e ROYAL VICTORIA HOSPITAL   (Canada)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

ApoB; BMI; DPP 4; Genetics; Incretin; Interaction; LDL cholesterol; SNPs

Indexed keywords

APOLIPOPROTEIN B; DIPEPTIDYL PEPTIDASE IV; RAMIPRIL; ROSIGLITAZONE;

ADULT; ARTICLE; ASIAN; BODY MASS; DIABETES MELLITUS; ETHNICITY; EUROPE; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH ASIA;

ADULT; APOLIPOPROTEINS B; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84896095873     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-3142-3     Document Type: Article

References (41)

1. McKeigue PM, Marmot MG, Syndercombe Court YD, Cottier DE, Rahman S, Riemersma RA (1988) Diabetes, hyperinsulinaemia, and coronary risk factors in Bangladeshis in east London. Br Heart J 60:390-396
2. Yusuf S, Hawken S, Ounpuu S et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:937-952 (Pubitemid 39208455)
3. Joshi P, Islam S, Pais P et al (2007) Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. J Am Med Assoc 297:286-294 (Pubitemid 46143306)
4. Ramachandran A, Snehalatha C, Viswanathan V, Viswanathan M, Haffner SM (1997) Risk of noninsulin dependent diabetes mellitus conferred by obesity and central adiposity in different ethnic groups: a comparative analysis between Asian Indians, Mexican Americans and Whites. Diabetes Res Clin Pract 36:121-125 (Pubitemid 27297005)
5. Mather HM, Chaturvedi N, Fuller JH (1998)Mortality and morbidity from diabetes in South Asians and Europeans: 11-year follow-up of the Southall Diabetes Survey, London, UK. Diabet Med 15:53-59 (Pubitemid 28113999)
6. Teslovich TM, Musunuru K, Smith AV et al (2010) Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466:707-713
7. Rosenberg NA, Huang L, Jewett EM, Szpiech ZA, Jankovic I, Boehnke M (2010) Genome-wide association studies in diverse populations. Nat Rev Gen 11:356-366
8. Mooradian AD (2009) Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 5:150-159
9. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB (2005) Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112:3375-3383 (Pubitemid 43739551)
10. Gerstein HC, Yusuf S, Bosch J et al (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096-1105
11. Anand SS, Dagenais GR, Mohan V et al (2012) Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. Eur J Prev Cardiol 19:755-764
12. Anand SS, Xie C, Pare G et al (2009) Genetic variants associated with myocardial infarction risk factors in over 8000 individuals from five ethnic groups: the INTERHEART Genetics Study. Circ Cardiovasc Genet 2:16-25
13. Keating BJ, Tischfield S, Murray SS et al (2008) Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PloS one 3:e3583
14. Purcell S, Neale B, Todd-Brown K et al (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81:559-575 (Pubitemid 47330214)
15. Timpson NJ, Lindgren CM, Weedon MN et al (2009) Adiposity-related heterogeneity in patterns of type 2 diabetes susceptibility observed in genome-wide association data. Diabetes 58:505-510
16. Perry JR, Voight BF, Yengo L et al (2012) Stratifying type 2 diabetes cases by BMI identifies genetic risk variants in LAMA1 and enrichment for risk variants in lean compared to obese cases. PLoS genetics 8:e1002741
17. Kooner JS, Saleheen D, Sim X et al (2011) Genome-wide association study in individuals of South Asian ancestry identifies six new type 2 diabetes susceptibility loci. Nat Genet 43:984-989
18. Bouchard L, Faucher G, Tchernof A et al (2009) Comprehensive genetic analysis of the dipeptidyl peptidase-4 gene and cardiovascular disease risk factors in obese individuals. Acta Diabetol 46:13-21
19. Turcot V, Bouchard L, Faucher G et al (2011) DPP4 gene DNA methylation in the omentum is associated with its gene expression and plasma lipid profile in severe obesity. Obesity (Silver Spring) 19:388-395
20. Sell H, Bluher M, Kloting N et al (2013) Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care 36:4083-4090
21. Bolli G, Dotta F, Colin L, Minic B, Goodman M (2009) Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab 11:589-595
22. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A (2007) Comparison of vildagliptin and rosiglitazonemonotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 30:217-223 (Pubitemid 46198322)
23. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29:2638-2643 (Pubitemid 44912191)
24. Ferrannini E, Fonseca V, Zinman B et al (2009) Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled onmetformin monotherapy. Diabetes Obes Metab 11:157-166
25. Rizzo M, Rizvi AA, Spinas GA, Rini GB, Berneis K (2009) Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin Invest Drugs 18:1495-1503
26. Horton ES, Silberman C, Davis KL, Berria R (2010) Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care 33:1759-1765
27. Kubota A, Maeda H, Kanamori A et al (2012) Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. J Clin Med Res 4:309-313
28. Monami M, Lamanna C, Desideri CM, Mannucci E (2012) DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther 29:14-25
29. Monami M, Vitale V, Ambrosio ML et al (2012) Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. Adv Ther 29:736-746
30. Flock G, Baggio LL, Longuet C, Drucker DJ (2007) Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 56:3006-3013 (Pubitemid 350223636)
31. Matikainen N, Manttari S, Schweizer A et al (2006) Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 49:2049-2057 (Pubitemid 44168471)
32. Kim SA, Shim WH, Lee EH et al (2011) Predictive clinical parameters for the therapeutic efficacy of sitagliptin in Korean type 2 diabetes mellitus. Diabetes Metab J 35:159-165
33. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705 (Pubitemid 46048557)
34. Rouille Y, Kantengwa S, Irminger JC, Halban PA (1997) Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1. J Biol Chem 272:32810-32816 (Pubitemid 28023615)
35. Benzinou M, Creemers JW, Choquet H et al (2008) Common nonsynonymous variants in PCSK1 confer risk of obesity. Nat Genet 40:943-945
36. Saxena R, Hivert MF, Langenberg C et al (2010) Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 42:142-148
37. Speliotes EK, Willer CJ, Berndt SI et al (2010) Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 42:937-948
38. Ussher JR, Drucker DJ (2012) Cardiovascular biology of the incretin system. Endocr Rev 33:187-215
39. Monami M, Ahren B, Dicembrini I, Mannucci E (2013) Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 15:112-120
40. Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317-1326
41. White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327-1335